India is pronto becoming one of the best-considered settings for global pharma's drug research and development (R&D). Many factors have contributed to this deploy attraction, namely: highly-skilled doctors, trained paramedical staff, and a strong research infrastructure.
Pharma Licensing Consultant firms attribute the growth in pharma sales to transitional disease profiles, bigger access to medicines, and growing public health programs, and if the Indian economy keeps on growing, the local pharmaceutical market will experience a huge transformation in the years to come, reaching the top 10 around the year 2015. This will definitely have an impact on the global pharma industry in regards to R&D.
There are various reasons as to why India is such a desired location for research and development:
India is expected to be the most populated country by 2035, turning it into the youngest one. It holds 20% of the world's population under 24.
This country has a varied patient population in regards to race, culture, and economic level; and many are inexperienced about treatment. They are less prepared to deal with pneumonia, Hepatitis B, diabetes, or cancer, thus, the more patients, the higher recruitment quota. Shorter recruitment timelines prevail in India and patients' compliance is higher, that’s where firms like Drug Regulatory Consultant in India comes to light.
Many of the issues regarding patent protection and intellectual property rights are settled. India is compliant with the Trade Related Intellectual Property Rights Act (TRIPS). It holds a first-class data-processing infrastructure for biostatistics and bioinformatics, and huge generic drug-manufacturing facilities.
All of these are critical aspects for R&D costs, which have dramatically been increasing for the past few years. It is vital to streamline the development process as much as possible.DCGI Consultant in Delhi/India provides a great base for Pharmaceutical consulting firms.
No comments:
Post a Comment